Skip to search formSkip to main contentSkip to account menu

Sitamaquine

Known as: 8-((6-(diethylamino)hexyl)amino)-6-methoxy-4-methylquinoline, N,N-diethyl-N'-(6-methoxy-4-methyl-8-quinolinyl)-1,6- hexanediamine 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

8-aminoquinoline

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
An update on small molecule strategies targeting leishmaniasis.
Review
2011
Review
2011
Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance
Sitamaquine is a 8-aminoquinoline in development for the treatment of visceral leishmaniasis by oral route, no activity being… 
Highly Cited
2011
Highly Cited
2011
The 8-Aminoquinoline Analogue Sitamaquine Causes Oxidative Stress in Leishmania donovani Promastigotes by Targeting Succinate Dehydrogenase
ABSTRACT The 8-aminoquinoline analogue sitamaquine (SQ) is an oral antileishmanial drug currently undergoing phase 2b clinical… 
Review
2006
Review
2006
Visceral leishmaniasis - current therapeutic modalities.
Major therapeutic obstacles in the treatment of visceral leishmaniasis (VL) include the alarming increase in antimonial… 
2006
2006
In‐vitro and in‐vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis
The efficacy of topical formulations of the 8‐aminoquinoline, sitamaquine dihydrochloride, in both in‐vitro and in in‐vivo models… 
Review
2006
Review
2006
8-Aminoquinolines: future role as antiprotozoal drugs
Purpose of review This review focuses on recent developments on evaluation of 8-aminoquinoline analogs with broader efficacy and… 
Highly Cited
2005
Highly Cited
2005
A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya.
Sitamaquine (WR6026) is an 8-aminoquinoline in development for the oral treatment of visceral leishmaniasis (VL). This was an… 
Highly Cited
2005
Highly Cited
2005
A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India.
This randomized, open label, multicenter study assessed the dose-response and safety profile for oral sitamaquine in 120 Indian… 
Review
2002
Review
2002
Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute).
Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in… 
Review
2002
Review
2002
Advances in the treatment of leishmaniasis
Purpose of review Treatment of leishmaniasis is far from satisfactory: all antileishmanial drugs are toxic and most have to be… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)